找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Novel Therapeutics from Modern Biotechnology; From Laboratory to H Dale L. Oxender,Leonard E. Post (Vice President, D Book 1999 Springer-Ve

[复制链接]
查看: 28639|回复: 46
发表于 2025-3-21 16:29:11 | 显示全部楼层 |阅读模式
书目名称Novel Therapeutics from Modern Biotechnology
副标题From Laboratory to H
编辑Dale L. Oxender,Leonard E. Post (Vice President, D
视频video
概述Study Edition of the successful volume 137 in the Handbook of Experimental Pharmacology series * Original edition already sold out.Includes supplementary material:
丛书名称Handbook of Experimental Pharmacology
图书封面Titlebook: Novel Therapeutics from Modern Biotechnology; From Laboratory to H Dale L. Oxender,Leonard E. Post (Vice President, D Book 1999 Springer-Ve
描述A cover story of Business Week Magazine in January 1984 stated "Biotech Comes of Age". In February 1986, Venture Magazine had a cover article entitled "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the "New Biology". . At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the "high-technology hype", although companies are still forming as the technology advances. A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotech­ nology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, suc
出版日期Book 1999
关键词Downstream Processing; Expression; Nucleotide; Tissue Engineering; Vivo; biotechnology; chemistry; chromato
版次1
doihttps://doi.org/10.1007/978-3-642-59990-3
isbn_softcover978-3-540-65927-3
isbn_ebook978-3-642-59990-3Series ISSN 0171-2004 Series E-ISSN 1865-0325
issn_series 0171-2004
copyrightSpringer-Verlag Berlin Heidelberg 1999
The information of publication is updating

书目名称Novel Therapeutics from Modern Biotechnology影响因子(影响力)




书目名称Novel Therapeutics from Modern Biotechnology影响因子(影响力)学科排名




书目名称Novel Therapeutics from Modern Biotechnology网络公开度




书目名称Novel Therapeutics from Modern Biotechnology网络公开度学科排名




书目名称Novel Therapeutics from Modern Biotechnology被引频次




书目名称Novel Therapeutics from Modern Biotechnology被引频次学科排名




书目名称Novel Therapeutics from Modern Biotechnology年度引用




书目名称Novel Therapeutics from Modern Biotechnology年度引用学科排名




书目名称Novel Therapeutics from Modern Biotechnology读者反馈




书目名称Novel Therapeutics from Modern Biotechnology读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:40:24 | 显示全部楼层
发表于 2025-3-22 00:32:06 | 显示全部楼层
发表于 2025-3-22 07:30:09 | 显示全部楼层
发表于 2025-3-22 12:48:48 | 显示全部楼层
发表于 2025-3-22 13:42:16 | 显示全部楼层
SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytiult in death. Infants with underlying cardiac or pulmonary disease, and some premature/low-birth-weight infants are at considerably higher risk of more severe disease and increased mortality from RSV infection, and are candidates for prophylactic intervention during the winter months. Although not w
发表于 2025-3-22 19:33:57 | 显示全部楼层
Book 1999cal trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, suc
发表于 2025-3-22 23:47:52 | 显示全部楼层
发表于 2025-3-23 01:53:50 | 显示全部楼层
发表于 2025-3-23 09:08:37 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-20 16:16
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表